CGRP Forum is made possible thanks to support from AbbVie, Organon and Pfizer, all of whom have no influence or control over editorial content. More information is available here »

Reassuring persistence rates with CGRP mAb therapy in adolescents and adults ECLIPSE analyses show consistent atogepant effects across multiple migraine attacks Premonitory symptoms during CGRP mAb therapy Who can ‘graduate’ from CGRP mAbs?Long term triple therapy in chronic migraine PACAP-38 is detectable in tears Eptinezumab improves migraine-related cognitive symptoms Benefits of adding atogepant to onabotulinumtoxinA for chronic migraine

Why is CGRP an important therapeutic target?

15 December 2016 | Posted by Peter Goadsby | Videos

Multiple lines of evidence support a role for CGRP in migraine pathophysiology. Its blockade is now a potentially important therapeutic target for migraine prevention.

Educational Partners and Supporters

This program is funded in part via an independent educational grant from AbbVie.

Organon has provided sponsorship towards this independent resource. Organon has had no editorial input or control over content, nor opportunity to influence.

Financial support was provided as GMG Knowledge Gap Grant from Pfizer Inc, Pfizer have provided only financial support and had no input into the content provided.

Editorial PolicyCGRP Forum is an expert resource for clinicians and healthcare professionals working with migraine patients. All patients should discuss their medication with their healthcare professional. Unless otherwise indicated, opinions expressed in the CGRP Education and Research Forum are those of the contributors. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the CGRP Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

© 2026 | Privacy Policy | Editorial Policy | Governance | Disclaimer Statement | Partnership & Outreach | Educational Partners and Supporters |